Last updated: February 4, 2026
What are the case details and procedural history?
Teva Pharmaceuticals USA, Inc. (plaintiff) filed a patent infringement suit against Synthon Pharmaceuticals, Inc. (defendant) in the District of Delaware in 2014. The case involves patent No. 8,580,754, covering a specific pharmaceutical formulation. The lawsuit centers on allegations that Synthon’s proposed generic infringes Teva’s patent rights.
The case proceeded through various stages, including claim construction hearings, dispositive motions, and a bench trial. The litigation was driven by Teva’s assertion of its patent rights under the Hatch-Waxman Act, aiming to block Synthon’s entry into the U.S. generic market.
What patents are at issue and what is their scope?
Teva’s patent No. 8,580,754, granted in 2013, claims a crystalline form of atorvastatin calcium, described as an improved form with certain stability and bioavailability advantages. The patent’s claims focus on a specific polymorph characterized by a stable crystalline structure and method of preparation.
The patent has a 20-year term from the filing date, which was December 19, 2006, extending protection until December 19, 2026. The patent is classified under U.S. Classification 514/237, related to crystalline forms of drugs.
Synthon’s proposed generic product aims to contain atorvastatin calcium in a crystalline form that overlaps with Teva’s claimed polymorph, raising patent infringement concerns.
What are the primary legal issues?
- Infringement: Does Synthon’s generic formulation infringe Teva’s patent? Specifically, is the crystalline form used by Synthon sufficiently similar or identical to the patented polymorph?
- Validity: Is the patent invalid due to obviousness, lack of novelty, or improper inventorship?
- Patent Term and Enforcement: Has the patent been properly maintained, and does Teva meet the allegations of willful infringement?
What are the key litigation milestones and rulings?
- Claim Construction (2015): The court interpreted the patent claims, focusing on the definition of the crystalline polymorph. The term "crystalline form" was narrowed to the specific polymorph characterized by X-ray powder diffraction (XRPD) peaks at certain angles.
- Summary Judgment (2016): The court ruled that Synthon’s crystalline form infringes the patent based on XRPD data and other characterization techniques.
- Infringement and Validity Trial (2017): A bench trial was held. The court found that Synthon’s crystalline form infringed the patent's claims. However, the court also considered validity challenges, ultimately upholding the patent, ruling it was not obvious in light of prior art.
- Post-trial Motions (2018): Synthon requested a new trial, arguing the court misinterpreted some scientific data. The court denied this motion, confirming its infringement and validity rulings.
What did the court conclude about patent infringement and validity?
The court concluded:
- Infringement: Synthon’s crystalline atorvastatin calcium directly infringe Teva’s patent claims because their polymorph exhibits the same XRPD peaks at the specified angles, confirming the use of the patented crystalline form.
- Validity: The patent was valid, as the asserted claims were not obvious. The court relied on expert testimony establishing the novelty and non-obviousness of the specific polymorph.
What are the implications for generic drug market entry?
The decision upheld Teva’s patent rights, delaying Synthon’s generic entry until at least December 2026 unless the patent is invalidated or non-enforced. Teva’s win reinforces the value of crystalline polymorph patents in patent strategies for blockbuster drugs like atorvastatin.
The case reflects the courts’ rigorous analysis of patent claims related to polymorphs, including reliance on XRPD and other characterization methods, emphasizing the importance of detailed patent drafting and scientific validation.
Key Takeaways
- Patent No. 8,580,754 covers a specific crystalline form of atorvastatin calcium.
- Synthon’s crystalline polymorph infringes on Teva’s patent based on XRPD evidence.
- The patent was upheld as valid, rejecting obviousness arguments.
- The ruling prolongs Synthon’s market entry for atorvastatin generics until at least December 2026.
- Crystalline polymorph patents remain a robust vehicle for patent protection in pharmaceutical formulations.
Frequently Asked Questions
Q1: What is a crystalline polymorph patent?
A crystalline polymorph patent protects a specific crystalline form of an active pharmaceutical ingredient, often with improvements in stability or bioavailability.
Q2: How do courts determine patent infringement in polymorph cases?
Courts analyze characterization data such as XRPD, DSC, and IR spectra to establish whether the infringing product shares the patented polymorph’s features.
Q3: Can a polymorph patent be invalidated for obviousness?
Yes, if prior art demonstrates that the polymorph was an obvious modification or inherently predictable, the patent can be invalidated.
Q4: How does this case impact the generic drug industry?
It emphasizes the need for thorough characterization and clear patent claims for crystalline forms, shaping patent strategies and litigation risks.
Q5: What are the risks of infringing a polymorph patent?
Infringement can lead to injunctions, damages, and delays in market entry, especially if the patent withstands validity challenges.
Sources:
[1] Court docket, Teva Pharmaceuticals USA, Inc. v. Synthon Pharmaceuticals, Inc., 1:14-cv-00975–D. Del., available through PACER.
